TMCnet News
Otsuka and Lundbeck to Present New Data on Brexpiprazole in Major Depressive Disorder (MDD) at European Psychiatry Association 2014 CongressTOKYO & COPENHAGEN, Denmark --(Business Wire)-- Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the first phase III data on their investigational compound brexpiprazole will be presented in an upcoming poster session at the 22nd European Psychiatry Association Congress (EPA) on March 2, 2014. Data will be presented from a completed phase III, randomized, placebo-controlled study investigating the effect of brexpiprazole as adjunctive therapy to antidepressant therapy in patients with major depressive disorder (MDD). Overall, brexpiprazole demonstrated efficacy and was well tolerated as an adjunctive treatment for MDD patients with an inadequate response to antidepressant treatment. At the EPA congress, highlighted data on brexpiprazole as adjunctive therapy to anti-depressant therapy in MDD will include:
Additional information provided in the poster presentation at the EPA congress will be publicly disclosed at that time. Otsuka and Lundbeck are running an extensive development program for brexpiprazole. Three additional studies in depression and schizophrenia will conclude in the first half of 2014. Phase III clinical trials are also underway in patients with agitation associated with dementia of the Alzheimer's type.
About brexpiprazole OPC-34712)
About Otsuka Pharmaceutical Co., Ltd. In pharmaceuticals, Otsuka is a leading firm in the challenging area of mental health and also has research programs for several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate more powerfully than words how Otsuka is a "big venture" company at heart, applying a youthful spirit of creativity in everything it does. Otsuka is a wholly owned subsidiary of Otsuka Holdings Co., Ltd., the holding company for the Otsuka Group. The chairman Akihiko Otsuka is the third generation of Otsuka family members to lead the business, whose origins date from 1921. The Otsuka Group employs approximately 42,000 people globally and its products are available in more than 80 countries worldwide. Consolidated sales were approximately €10 billion or USD 13 billion for fiscal year 2012 (4/1/2012-3/31/2013). Otsuka Pharmaceutical welcomes you to visit its global website at https://www.otsuka.co.jp/en/
About H. Lundbeck A/S Lundbeck employs more than 5,800 people worldwide, 2,000 of whom are based in Denmark. We have research in 57 countries and our products are registered in more than 100 countries. We have research centers in Denmark, China and the United States and production facilities in Italy, France, Mexico, China and Denmark. Lundbeck generated revenue of approximately DKK 15 billion in 2012. For additional information, we encourage you to visit our corporate site www.lundbeck.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140123006518/en/ |